Lux Biosciences Announces Multiple Presentations on LX211 at Upcoming American Academy of Ophthalmology and American Uveitis Society Annual Meetings

JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company’s experimental drug LX211 (LUVENIQ™; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco. Lux Biosciences plans to file an NDA and MAA for marketing approvals of LX211 in the United States and Europe, respectively around year-end 2009. If approved, LX211 may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions previously inevitably associated with either severe vision loss or substantial morbidity from steroid use.

Back to news